New Delhi, Feb. 3 -- US-based pharmaceutical company Eli Lilly is planning to launch Mounjaro, an anti-diabetes and weight loss drug in India by 2025 after regulatory approvals, reported News18 citing officials from the company.

Eli Lilly sells Tirzepetide under the name of Mounjaro, a prescription-based medication that has to be injected once a week. It helps to manage obesity and diabetes, which is a serious disease and not only a cosmetic issue, according to the company.

The company has not finalised the price of the drug.

We haven't yet finalised the pricing strategy for the Tirzapedite, but our pricing will reflect the medicine's efficacy and the fact that it improves overall health and reduces the economic burden attached to diab...